scispace - formally typeset
V

Vesela Encheva

Researcher at Francis Crick Institute

Publications -  39
Citations -  1984

Vesela Encheva is an academic researcher from Francis Crick Institute. The author has contributed to research in topics: Proteome & DNA damage. The author has an hindex of 20, co-authored 38 publications receiving 1500 citations. Previous affiliations of Vesela Encheva include Health Protection Agency & Imperial College London.

Papers
More filters
Journal ArticleDOI

Naive pluripotency is associated with global DNA hypomethylation

TL;DR: It is established that culture in 2i instills a naive pluripotent state with a distinctive epigenetic configuration that parallels molecular features observed in both the preimplantation epiblast and nascent PGCs.
Journal ArticleDOI

De novo DNA methylation drives 5hmC accumulation in mouse zygotes

TL;DR: It is demonstrated using detailed immunofluorescence analysis and ultrasensitive LC-MS-based quantitative measurements that the initial loss of paternal 5mC does not require 5hmC formation, and an intricate interplay between DNA demethylation, de novo methylation and Tet3-driven hydroxylation is revealed.
Journal ArticleDOI

Multiomic Analysis of the UV-Induced DNA Damage Response.

TL;DR: A role for the poorly studied, melanoma-associated serine/threonine kinase 19 (STK19) is uncovered, which provides a systems-wide overview of the diverse cellular processes connected to the transcription-related DNA damage response.
Journal ArticleDOI

Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway

TL;DR: The data show that integrin β3 subunit is a marker and regulator of senescence and shows an increase in β3 levels in a subset of tissues during aging.
Journal ArticleDOI

USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination

TL;DR: It is found that the β-catenin inhibitory domain in APC represents the threshold for pathological levels of Wnt activation and tumor transformation and the Wnt-activating role of USP7 is specific to APC mutations; thus, it can be used as a tumor-specific therapeutic target for most CRCs.